Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot

Alexander Egbe, William R. Miranda, Naser M. Ammash, Venkata R. Missula, Raja Jadav, Maria Najam, Srikanth Kothapalli, Heidi M. Connolly

Research output: Contribution to journalArticle

Abstract

Background Available outcomes data for anticoagulation therapy in adults with congenital heart disease ( CHD ) provide assessment of global risk of this therapy for CHD patients (a heterogeneous population), but the risk of complications for the different CHD diagnoses is unknown. The purpose of the study was to describe the indications for anticoagulation, and the incidence and risk factors for major bleeding complication in adults with tetralogy of Fallot. Methods and Results We queried Mayo Adult Congenital Heart Disease (MACHD) database for tetralogy of Fallot patients (aged ≥18 years) that received anticoagulation, 1990-2017. Of 130 patients (42±14 years, 75 men [58%]), warfarin and direct oral anticoagulants were used in 125 (96%) and 5 (4%), respectively because atrial arrhythmias (n=109), mechanical prosthetic valve (n=29), intracardiac thrombus (n=4), pulmonary embolism (n=6), stroke (n=3), and perioperative anticoagulation (n=44). The median hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score for the entire cohort was 1 (0-2) and 27 (21%) had hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2. There were 14 minor bleeding events (1.6% per year) and 11 major bleeding events (1.3% per year) in 8 patients during median follow-up of 74 months (856 patient-years). Mechanical prosthesis (hazard ratio 1.78, CI 1.29-3.77, P=0.021) and hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2 (hazard ratio 1.41, CI 1.03-3.88, P=0.046) were risk factors for major bleeding events. All-cause mortality was higher in patients with major bleeding events (n=6, 75%) compared with patients without major bleeding events (n=25, 21%), P=0.001. Conclusions Considering the heterogeneity of the CHD population, data from the current study may be better suited for clinical decision-making in tetralogy of Fallot patients.

Original languageEnglish (US)
Pages (from-to)e011474
JournalJournal of the American Heart Association
Volume8
Issue number5
DOIs
StatePublished - Mar 5 2019

Fingerprint

Tetralogy of Fallot
Hemorrhage
Heart Diseases
Renal Hypertension
International Normalized Ratio
Stroke
Therapeutics
Alcohols
Liver
Pharmaceutical Preparations
Warfarin
Pulmonary Embolism
Anticoagulants
Population
Prostheses and Implants
Cardiac Arrhythmias
Thrombosis
Databases
Mortality
Incidence

Keywords

  • anticoagulation
  • bleeding
  • stroke
  • tetralogy of Fallot
  • thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Egbe, A., Miranda, W. R., Ammash, N. M., Missula, V. R., Jadav, R., Najam, M., ... Connolly, H. M. (2019). Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot. Journal of the American Heart Association, 8(5), e011474. https://doi.org/10.1161/JAHA.118.011474

Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot. / Egbe, Alexander; Miranda, William R.; Ammash, Naser M.; Missula, Venkata R.; Jadav, Raja; Najam, Maria; Kothapalli, Srikanth; Connolly, Heidi M.

In: Journal of the American Heart Association, Vol. 8, No. 5, 05.03.2019, p. e011474.

Research output: Contribution to journalArticle

Egbe, A, Miranda, WR, Ammash, NM, Missula, VR, Jadav, R, Najam, M, Kothapalli, S & Connolly, HM 2019, 'Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot', Journal of the American Heart Association, vol. 8, no. 5, pp. e011474. https://doi.org/10.1161/JAHA.118.011474
Egbe, Alexander ; Miranda, William R. ; Ammash, Naser M. ; Missula, Venkata R. ; Jadav, Raja ; Najam, Maria ; Kothapalli, Srikanth ; Connolly, Heidi M. / Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot. In: Journal of the American Heart Association. 2019 ; Vol. 8, No. 5. pp. e011474.
@article{b94d0d30258f4d1aa16d50225e682557,
title = "Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot",
abstract = "Background Available outcomes data for anticoagulation therapy in adults with congenital heart disease ( CHD ) provide assessment of global risk of this therapy for CHD patients (a heterogeneous population), but the risk of complications for the different CHD diagnoses is unknown. The purpose of the study was to describe the indications for anticoagulation, and the incidence and risk factors for major bleeding complication in adults with tetralogy of Fallot. Methods and Results We queried Mayo Adult Congenital Heart Disease (MACHD) database for tetralogy of Fallot patients (aged ≥18 years) that received anticoagulation, 1990-2017. Of 130 patients (42±14 years, 75 men [58{\%}]), warfarin and direct oral anticoagulants were used in 125 (96{\%}) and 5 (4{\%}), respectively because atrial arrhythmias (n=109), mechanical prosthetic valve (n=29), intracardiac thrombus (n=4), pulmonary embolism (n=6), stroke (n=3), and perioperative anticoagulation (n=44). The median hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score for the entire cohort was 1 (0-2) and 27 (21{\%}) had hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2. There were 14 minor bleeding events (1.6{\%} per year) and 11 major bleeding events (1.3{\%} per year) in 8 patients during median follow-up of 74 months (856 patient-years). Mechanical prosthesis (hazard ratio 1.78, CI 1.29-3.77, P=0.021) and hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2 (hazard ratio 1.41, CI 1.03-3.88, P=0.046) were risk factors for major bleeding events. All-cause mortality was higher in patients with major bleeding events (n=6, 75{\%}) compared with patients without major bleeding events (n=25, 21{\%}), P=0.001. Conclusions Considering the heterogeneity of the CHD population, data from the current study may be better suited for clinical decision-making in tetralogy of Fallot patients.",
keywords = "anticoagulation, bleeding, stroke, tetralogy of Fallot, thromboembolism",
author = "Alexander Egbe and Miranda, {William R.} and Ammash, {Naser M.} and Missula, {Venkata R.} and Raja Jadav and Maria Najam and Srikanth Kothapalli and Connolly, {Heidi M.}",
year = "2019",
month = "3",
day = "5",
doi = "10.1161/JAHA.118.011474",
language = "English (US)",
volume = "8",
pages = "e011474",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Outcomes of Anticoagulation Therapy in Adults With Tetralogy of Fallot

AU - Egbe, Alexander

AU - Miranda, William R.

AU - Ammash, Naser M.

AU - Missula, Venkata R.

AU - Jadav, Raja

AU - Najam, Maria

AU - Kothapalli, Srikanth

AU - Connolly, Heidi M.

PY - 2019/3/5

Y1 - 2019/3/5

N2 - Background Available outcomes data for anticoagulation therapy in adults with congenital heart disease ( CHD ) provide assessment of global risk of this therapy for CHD patients (a heterogeneous population), but the risk of complications for the different CHD diagnoses is unknown. The purpose of the study was to describe the indications for anticoagulation, and the incidence and risk factors for major bleeding complication in adults with tetralogy of Fallot. Methods and Results We queried Mayo Adult Congenital Heart Disease (MACHD) database for tetralogy of Fallot patients (aged ≥18 years) that received anticoagulation, 1990-2017. Of 130 patients (42±14 years, 75 men [58%]), warfarin and direct oral anticoagulants were used in 125 (96%) and 5 (4%), respectively because atrial arrhythmias (n=109), mechanical prosthetic valve (n=29), intracardiac thrombus (n=4), pulmonary embolism (n=6), stroke (n=3), and perioperative anticoagulation (n=44). The median hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score for the entire cohort was 1 (0-2) and 27 (21%) had hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2. There were 14 minor bleeding events (1.6% per year) and 11 major bleeding events (1.3% per year) in 8 patients during median follow-up of 74 months (856 patient-years). Mechanical prosthesis (hazard ratio 1.78, CI 1.29-3.77, P=0.021) and hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2 (hazard ratio 1.41, CI 1.03-3.88, P=0.046) were risk factors for major bleeding events. All-cause mortality was higher in patients with major bleeding events (n=6, 75%) compared with patients without major bleeding events (n=25, 21%), P=0.001. Conclusions Considering the heterogeneity of the CHD population, data from the current study may be better suited for clinical decision-making in tetralogy of Fallot patients.

AB - Background Available outcomes data for anticoagulation therapy in adults with congenital heart disease ( CHD ) provide assessment of global risk of this therapy for CHD patients (a heterogeneous population), but the risk of complications for the different CHD diagnoses is unknown. The purpose of the study was to describe the indications for anticoagulation, and the incidence and risk factors for major bleeding complication in adults with tetralogy of Fallot. Methods and Results We queried Mayo Adult Congenital Heart Disease (MACHD) database for tetralogy of Fallot patients (aged ≥18 years) that received anticoagulation, 1990-2017. Of 130 patients (42±14 years, 75 men [58%]), warfarin and direct oral anticoagulants were used in 125 (96%) and 5 (4%), respectively because atrial arrhythmias (n=109), mechanical prosthetic valve (n=29), intracardiac thrombus (n=4), pulmonary embolism (n=6), stroke (n=3), and perioperative anticoagulation (n=44). The median hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score for the entire cohort was 1 (0-2) and 27 (21%) had hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2. There were 14 minor bleeding events (1.6% per year) and 11 major bleeding events (1.3% per year) in 8 patients during median follow-up of 74 months (856 patient-years). Mechanical prosthesis (hazard ratio 1.78, CI 1.29-3.77, P=0.021) and hypertension, abnormal renal or liver function; stroke; bleeding history or predisposition; labile international normalized ratio; elderly (>65 years); drug or alcohol use score ≥2 (hazard ratio 1.41, CI 1.03-3.88, P=0.046) were risk factors for major bleeding events. All-cause mortality was higher in patients with major bleeding events (n=6, 75%) compared with patients without major bleeding events (n=25, 21%), P=0.001. Conclusions Considering the heterogeneity of the CHD population, data from the current study may be better suited for clinical decision-making in tetralogy of Fallot patients.

KW - anticoagulation

KW - bleeding

KW - stroke

KW - tetralogy of Fallot

KW - thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85062179407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062179407&partnerID=8YFLogxK

U2 - 10.1161/JAHA.118.011474

DO - 10.1161/JAHA.118.011474

M3 - Article

C2 - 30803288

AN - SCOPUS:85062179407

VL - 8

SP - e011474

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 5

ER -